Literature DB >> 30867302

Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.

Elena Criscuolo1, Matteo Castelli1, Roberta A Diotti1, Virginia Amato1, Roberto Burioni1, Massimo Clementi1,2, Alessandro Ambrosi3, Nicasio Mancini1,2, Nicola Clementi4.   

Abstract

Herpes simplex virus 1 (HSV-1) and HSV-2 can evade serum antibody-mediated neutralization through cell-to-cell transmission mechanisms, which represent one of the central steps in disease reactivation. To address the role of humoral immunity in controlling HSV-1 and HSV-2 replication, we analyzed serum samples from 44 HSV-1 and HSV-2 seropositive subjects by evaluating (i) their efficiency in binding both the purified viral particles and recombinant gD and gB viral glycoproteins, (ii) their neutralizing activity, and (iii) their capacity to inhibit the cell-to-cell virus passage in vitro All of the sera were capable of binding gD, gB, and whole virions, and all sera significantly neutralized cell-free virus. However, neither whole sera nor purified serum IgG fraction was able to inhibit significantly cell-to-cell virus spreading in in vitro post-virus-entry infectious assays. Conversely, when spiked with an already described anti-gD human monoclonal neutralizing antibody capable of inhibiting HSV-1 and -2 cell-to-cell transmission, each serum boosted both its neutralizing and post-virus-entry inhibitory activity, with no interference exerted by serum antibody subpopulations.IMPORTANCE Despite its importance in the physiopathology of HSV-1 and -2 infections, the cell-to-cell spreading mechanism is still poorly understood. The data shown here suggest that infection-elicited neutralizing antibodies capable of inhibiting cell-to-cell virus spread can be underrepresented in most infected subjects. These observations can be of great help in better understanding the role of humoral immunity in controlling virus reactivation and in the perspective of developing novel therapeutic strategies, studying novel correlates of protection, and designing effective vaccines.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  cell-to-cell virus spread; herpes simplex virus; human monoclonal antibodies; humoral immunity; neutralizing activity; serum neutralizing antibodies

Mesh:

Substances:

Year:  2019        PMID: 30867302      PMCID: PMC6532082          DOI: 10.1128/JVI.00070-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions.

Authors:  Florent C Bender; Minu Samanta; Ekaterina E Heldwein; Manuel Ponce de Leon; Elina Bilman; Huan Lou; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

2.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

3.  Capturing the herpes simplex virus core fusion complex (gB-gH/gL) in an acidic environment.

Authors:  Tina M Cairns; J Charles Whitbeck; Huan Lou; Ekaterina E Heldwein; Tirumala K Chowdary; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

4.  Characterization of cell-cell fusion mediated by herpes simplex virus 2 glycoproteins gB, gD, gH and gL in transfected cells.

Authors:  Martin I Muggeridge
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

5.  Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Authors:  Adalbert Krawczyk; Jürgen Krauss; Anna M Eis-Hübinger; Martin P Däumer; Robert Schwarzenbacher; Ulf Dittmer; Karl E Schneweis; Dirk Jäger; Michael Roggendorf; Michaela A E Arndt
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

6.  Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization.

Authors:  Eric Lazear; J Charles Whitbeck; Manuel Ponce-de-Leon; Tina M Cairns; Sharon H Willis; Yi Zuo; Claude Krummenacher; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

7.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Authors:  L Corey; A G Langenberg; R Ashley; R E Sekulovich; A E Izu; J M Douglas; H H Handsfield; T Warren; L Marr; S Tyring; R DiCarlo; A A Adimora; P Leone; C L Dekker; R L Burke; W P Leong; S E Straus
Journal:  JAMA       Date:  1999-07-28       Impact factor: 56.272

8.  Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes.

Authors:  Brian S Sheridan; Thomas L Cherpes; Julie Urban; Pawel Kalinski; Robert L Hendricks
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities.

Authors:  A Gonzalez-Quintela; R Alende; F Gude; J Campos; J Rey; L M Meijide; C Fernandez-Merino; C Vidal
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

View more
  5 in total

1.  Antiviral CD19+CD27+ Memory B Cells Are Associated with Protection from Recurrent Asymptomatic Ocular Herpesvirus Infection.

Authors:  Nisha R Dhanushkodi; Swayam Prakash; Ruchi Srivastava; Pierre-Gregoire A Coulon; Danielle Arellano; Rayomand V Kapadia; Raian Fahim; Berfin Suzer; Leila Jamal; Hawa Vahed; Lbachir BenMohamed
Journal:  J Virol       Date:  2022-01-05       Impact factor: 6.549

2.  Extracellular vesicles originating from autophagy mediate an antibody-resistant spread of classical swine fever virus in cell culture.

Authors:  Tao Wang; Liang Zhang; Wulong Liang; Shanchuan Liu; Wen Deng; Yangruiyu Liu; Yaru Liu; Mengzhao Song; Kangkang Guo; Yanming Zhang
Journal:  Autophagy       Date:  2021-11-05       Impact factor: 13.391

3.  B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin.

Authors:  Emily S Ford; Anton M Sholukh; RuthMabel Boytz; Savanna S Carmack; Alexis Klock; Khamsone Phasouk; Danica Shao; Raabya Rossenkhan; Paul T Edlefsen; Tao Peng; Christine Johnston; Anna Wald; Jia Zhu; Lawrence Corey
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

4.  Ancient herpes simplex 1 genomes reveal recent viral structure in Eurasia.

Authors:  Meriam Guellil; Lucy van Dorp; Sarah A Inskip; Jenna M Dittmar; Lehti Saag; Kristiina Tambets; Ruoyun Hui; Alice Rose; Eugenia D'Atanasio; Aivar Kriiska; Liivi Varul; A M H C Koekkelkoren; Rimma D Goldina; Craig Cessford; Anu Solnik; Mait Metspalu; Johannes Krause; Alexander Herbig; John E Robb; Charlotte J Houldcroft; Christiana L Scheib
Journal:  Sci Adv       Date:  2022-07-27       Impact factor: 14.957

5.  Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity.

Authors:  Clare Burn Aschner; David M Knipe; Betsy C Herold
Journal:  NPJ Vaccines       Date:  2020-05-07       Impact factor: 9.399

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.